ALKEM.NS Cash Flow
Alkem Laboratories Ltd.
Profit & Loss Balance Sheet Cash Flow
Cash Flow · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 21:34
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Net Cash from Operating Activities | ₹16.82 Bn | ₹19.48 Bn | ₹19.13 Bn | ₹19.63 Bn | CashFlowsFromUsedInOperatingActivities |
| Net Cash from Investing Activities | ₹1.13 Bn | ₹-10.09 Bn | ₹-12.99 Bn | ₹-16.67 Bn | CashFlowsFromUsedInInvestingActivities |
| Net Cash from Financing Activities | ₹-17.61 Bn | ₹-11.45 Bn | ₹-8.11 Bn | ₹-5.03 Bn | CashFlowsFromUsedInFinancingActivities |
| Effect of Exchange Rate Changes | ₹0.07 Bn | ₹-0.02 Bn | ₹0.11 Bn | ₹-0.14 Bn | EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| Net Increase/(Decrease) in Cash | ₹0.42 Bn | ₹-2.07 Bn | ₹-1.86 Bn | ₹-2.22 Bn | IncreaseDecreaseInCashAndCashEquivalents |
| Cash and Cash Equivalents (Closing) | ₹2.32 Bn | ₹2.74 Bn | N/A | N/A | CashAndCashEquivalentsCashFlowStatement |
Every figure above is the exact value of the named XBRL element from ALKEM.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).